Ongoing PFS of >3 years in a patient with metastatic cholangiocarcinoma treated with durvalumab + chemotherapy

a day ago
Prof. Thomas Yau
Prof. Thomas YauSpecialist in Medical Oncology; School of Clinical Medicine; The University of Hong Kong, Hong Kong
Dr. Jeffrey Wong
Dr. Jeffrey WongFellow in Medical Oncology; Hong Kong
Prof. Thomas Yau
Prof. Thomas Yau Specialist in Medical Oncology; School of Clinical Medicine; The University of Hong Kong, Hong Kong
Dr. Jeffrey Wong
Dr. Jeffrey Wong Fellow in Medical Oncology; Hong Kong
Ongoing PFS of >3 years in a patient with metastatic cholangiocarcinoma treated with durvalumab + chemotherapy



References:

  1. NEJM Evid 2022;1:EVIDoa2200015.
  2. NCCN Clinical Practice Guidelines in Oncology, Biliary Tract Cancers, version 2.2025.
  3. J Hepatol 2025;83:1092-1101.
  4. ESMO Open 2025;10:104003.
The above content is for medical education purpose supported by AstraZeneca (Hong Kong) Limited.
HK-12653 22 Jan 2026

Related MIMS Drugs